OGNOrganon & Co.

1. Jul 31, 2026Supplemental Financial Information.Regulation FD disclosure · press release
2. Jul 17, 2026As previously disclosed, on April 26, 2026, Organon & Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Sun Pharmaceutical Holdings USA, Inc. (“Sun Pharma USA”), and Sun Pharma America, Inc., a wholly owned subsidiary of Sun …Other event · Form 8-K
3. Jun 11, 2026The stockholders of Organon & Co. (the “Company”) approved an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan (the “Amended and Restated 2021 ISP”) at the Company’s 2026 Annual Meeting held on June 9, 2026 (the “Annual Meeting”)Director or officer change · Form 8-K
4. Apr 30, 2026Organon Reports Results for the First Quarter.Earnings release · press release
5. Apr 27, 2026On April 26, 2026, Organon & Co. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation (“Parent”), Sun Pharma America, Inc., a Delaware corporation and wholly owned subsidiary of Parent and/or its affiliates (“Merger …Material agreement entered · Form 8-K
6. Feb 20, 2026As previously disclosed on February 12, 2026, the Audit Committee of the Board of Directors of Organon & Co. (the “Company”) conducted an independent review of the information brought to the Audit Committee’s attention on February 11, 2026 relating to the timing of the Company’s purchases of biosimilars from a …Other event · Form 8-K
7. Feb 12, 2026Organon Reports Results for the Fourth Quarter.Earnings release · press release
8. Nov 10, 2025Organon Reports Results for the Third Quarter.Earnings release · press release
9. Nov 7, 2025On November 3, 2025, Grace Puma informed Organon & Co. (the “Company”) that she will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
10. Oct 30, 2025There are no other changes to the information contained in the Original Form 8-K.Director or officer change · Form 8-K/A
11. Oct 27, 2025Separation of Kevin Ali On October 26, 2025, Kevin Ali resigned as Chief Executive Officer of Organon & Co. (the “Company”) and as a member of the Company’s Board of Directors (the “Board”) in connection with the investigation referred to in.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.